Biogen Inc (BIIB)

261.69
-5.76(-2.15%)
After Hours
261.69
0.00(0.00%)
- Real-time Data
  • Volume:
    1,562,008
  • Day's Range:
    257.51 - 266.43
  • 52 wk Range:
    187.16 - 290.76

BIIB Overview

Prev. Close
267.45
Day's Range
257.51-266.43
Revenue
10.82B
Open
265.28
52 wk Range
187.16-290.76
EPS
14.01
Volume
1,562,008
Market Cap
37.97B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,298,007
P/E Ratio
14.81
Beta
0.425
1-Year Change
-6.69%
Shares Outstanding
145,113,047
Next Earnings Date
Oct 25, 2022
What is your sentiment on Biogen?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Biogen Inc Analysis

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Read More

Analyst Price Target

Average268.72 (+2.69% Upside)
High360
Low190
Price261.69
No. of Analysts32
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyBuyBuy
Technical IndicatorsSellSellStrong SellStrong BuySell
SummaryStrong SellSellNeutralStrong BuyNeutral
  • lecanemab showed statistically significant results, but the effect seems to be too small to notice for most AD patients..
    0
    • heading to $2,000 and a 300 billion market cal
      1
      • Bios getting less risky as some have a pile of gold hidden within. BIIB good example. $300/ shr.
        1
        • Stock Split?
          4
          • No, its up on positive outcome on new Alzheimer’s drug!
            0
        • Etude positive sur lecanemab positive study on lecanemab🤑
          0
          • Yes, was published last night on Bloomberg. Mine sold at open today for $283 b/c I wasn't expecting an announcement this year, so had set open order sell on a bounce to $212, and was gonna buy back at $195 on the stock market's next leg lower in a month or few. Having owned BIIB and ESALY (Biogen's Japanese biotech partner on these Alzheimer's treatments), I've been following these drug studies since 2017-18 through a high dollar biotech research publication. Both this and the earlier approved drug both work for a large number of Alzheimer's patient. FDA and Medicare just want patients to realize it won't work for a large portion of Alzheimer's patients. But helping even a sizeable minority to a substantial improvement is better than ANYTHING we have today. It reminds me of AZT during late 1980s to mid 1990s; it wasn't great and had serious flaws, but it still saved lives and was better than any other option, or the early treatments for COVID. Over time, the industry will learn how to improve therapy now that we have something that works for a large number of patients.
            0
        • same named company is also listen in indian market.. Biogen
          1
          • Waiting for a breakthrough !A great entry point now , as I think , I bought 220 , I think the rocket is fueled here . Just be smarter , dump on time , otherwise you will become a bag holder
            1
            • Samsung!
              2
              • 01708620849
                0
                • is better to buy RTX US defense company . don't risk your money in Biogen .
                  0